Overview
BCR-ABL testing detects BCR-ABL1 fusion RNA (commonly e13a2/e14a2 p210 or e1a2 p190) by RT-qPCR and reports quantified disease burden, often on the International Scale (IS) for CML.
Clinical Importance
Diagnose CML/Ph+ disease adjunctively with cytogenetics/FISH
Monitor deep molecular response on tyrosine kinase inhibitor therapy
Specimen Requirements
- Specimen: whole blood or plasma as validated for the assay
- Tube: lavender-top K₂EDTA (preferred for many viral load and germline DNA assays)
- Handling: mix gently; separate plasma promptly when required; avoid heparin for many PCR assays (inhibition)
- Storage: refrigerate or freeze plasma per IFU; extract nucleic acid within validated windows
- Bone marrow may be used at diagnosis per protocol; peripheral blood preferred for serial monitoring when validated
Analytical Method
RNA is reverse-transcribed and amplified with fusion-specific primers/probes. Results are normalized to a control gene and converted to % IS when the laboratory is standardized. Undetectable levels are reported relative to assay MR depth (e.g., MR4, MR4.5) per IFU.
Instruments Used
Automated analyzers
- Applied Biosystems / Thermo Fisher real-time PCR systems (e.g., QuantStudio-class)
- Roche Cobas molecular / LightCycler systems
- Cepheid GeneXpert cartridge PCR systems
- BioFire FilmArray syndromic PCR systems
- Illumina next-generation sequencing platforms
- Thermo Fisher Ion Torrent sequencing platforms
- Digital PCR systems (e.g., Bio-Rad QX / QIAGEN QIAcuity-class)
- Specialized BCR-ABL quantitative PCR systems / kits
Manual methods
- Manual RNA/DNA extraction with real-time PCR or sequencing workflows
Reference Values
Molecular cutoffs, units (IU/mL, copies/mL, Ct), reportable ranges, and variant classifications are assay- and laboratory-specific. Always interpret against the performing laboratory report, manufacturer IFU, and current CLSI / CAP / AMP / ACMG guidance as adopted locally. Limit of detection and inhibition controls are essential for negative results.
At diagnosis: detectable fusion expected in CML. On TKI therapy: milestones use % IS (e.g., early response and MMR definitions per hematology guidelines); use current ELN/NCCN-style guidance adopted locally with the report’s IS value.
Interpretation
Critical molecular findings (e.g., new HIV RNA, high viral loads in transplant patients, actionable oncology variants per institutional lists) follow urgent-notification pathways. Confirm the local call list. Textbook examples are not universal thresholds.
Critical values
- Unexpected loss of MMR or rising transcripts often require urgent clinician notification
Common Causes of Increased Results
- Rising % IS; suggests loss of response; confirm with repeat and clinical/TKI review
Common Causes of Decreased Results
- Falling / deep molecular response; supports TKI efficacy when milestones met
Clinical Significance
- CML monitoring
- Ph+ ALL molecular follow-up
Factors Affecting Results
Pre-analytical
- RNA degradation from delayed processing
- Wrong sample type for the validated monitoring assay
Analytical
- PCR inhibition (heparin, humic acids, excess hemoglobin; assay-dependent)
- Extraction failure or pipetting/contamination in amplification areas
- Probe/primer mismatch with sequence variants causing false negatives
- Calibration/QC failure; expired reagents
Post-analytical
- Comparing non-IS values across laboratories as if identical
Advantages and Limitations
Advantages
- Quantitative IS monitoring standard in CML
Limitations
- Does not replace cytogenetic assessments when indicated
- Atypical breakpoints need specialized assays
Clinical Pearls
BCR-ABL trends only work on the International Scale; raw copies without IS are a dialect, not a language.
References
Authoritative textbooks, guidelines, and reviews supporting this laboratory test reference. Verify reference intervals, critical limits, and method details against institutional protocols and current guideline editions.
Textbooks
- McPherson RA, Pincus MR. Henry's Clinical Diagnosis and Management by Laboratory Methods. 24th ed. Elsevier; 2021. (Molecular diagnostics chapters, verify current edition.)
- Buckingham L. Molecular Diagnostics: Fundamentals, Methods, and Clinical Applications. 3rd ed. F.A. Davis; 2019. (Verify current edition and institutional adoption.)
CLSI and Professional Guidelines
- Clinical and Laboratory Standards Institute (CLSI). Consult current CLSI molecular method documents available through your laboratory, document numbers and editions change; do not treat any single CLSI title as universal.
- Institutional molecular laboratory standard operating procedures (SOPs), assay manufacturer instructions for use (IFU), and locally adopted accreditation requirements. Always verify current local practice.
- Clinical and Laboratory Standards Institute (CLSI). Molecular method evaluation and related documents (verify current CLSI editions applicable to the assay).
- College of American Pathologists. Molecular pathology accreditation and proficiency testing expectations (verify current CAP checklist requirements).
- Association for Molecular Pathology (AMP). Practice guidelines and position statements for molecular diagnostics (verify current AMP documents for the assay).
- American College of Medical Genetics and Genomics (ACMG). Standards and guidelines for interpretation of sequence variants and related genetic testing practice (verify current ACMG documents).
WHO Publications
- World Health Organization. Laboratory and diagnostic guidance relevant to molecular testing (verify current WHO publication for the assay/pathogen).
Frequently Asked Questions
Common questions about using this BCR-ABL laboratory test Medical Laboratory Library reference in Medical Laboratory Science education.
What is the BCR-ABL laboratory test reference used for?
This Medical Laboratory Library page summarizes the clinical importance of BCR-ABL. Review the Clinical Importance section for why the test is ordered in laboratory medicine practice.
Where can I find BCR-ABL specimen requirements?
See the Specimen Requirements section on this page for specimen information related to BCR-ABL. Confirm collection details against your laboratory protocol.
Where are BCR-ABL reference values listed?
See the Reference Values section on this Laboratory Library page. Reference ranges can vary by method and population, so verify intervals with your laboratory.
How do I interpret BCR-ABL results?
Use the Interpretation section for laboratory interpretation framing, including increased and decreased result patterns when provided. Do not treat educational text as a patient-specific diagnosis.
What analytical method is used for BCR-ABL?
See the Analytical Method section for principle and method notes. Method details may differ by instrument and institutional SOP.
Are related laboratory tests linked from BCR-ABL?
Yes. The Related Laboratory Tests section lists connected references for continued lookup in the Medical Laboratory Library.
How can I continue learning after reading BCR-ABL?
Use Continue learning links on this page for related Academy lessons, medical laboratory quizzes, or laboratory case studies when available for this Molecular Diagnostics topic.
What are the clinical pearls for BCR-ABL?
See the Clinical Pearls section for concise laboratory practice notes associated with BCR-ABL. Apply pearls alongside institutional protocols.
Reading progress
Awards XP once after you have meaningfully reviewed this article.